NCHRC Testifies at the FDA on the Role of Naloxone in Opioid Overdose Fatality Prevention;
04/12/2012
The Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER), in collaboration with the Office of the Assistant Secretary for Health, National Institutes of Drug Abuse and the Centers for Disease Control and Prevention, is announcing a scientific workshop to initiate a public discussion about the potential value of making naloxone more widely available outside of conventional medical settings to reduce the incidence of opioid overdose fatalities. Academia, government, industry experts and patient advocates will be assembled to discuss which populations are at-risk for opioid overdose and how public health groups are working together to curb the abuse of opioids. We will also seek to identify potential health concerns, social concerns, legal concerns, regulatory issues and future research needs related to making naloxone more widely available.
Date: April 12, 2012
Time: 8:30 a.m. to 5:30 p.m.
Location: FDA White Oak Campus
10903 New Hampshire Avenue
Bldg. 31 Conference Center
Silver Spring, MD 20993
